1. Additional file 1 of Projecting vaccine demand and impact for emerging zoonotic pathogens
- Author
-
Lerch, Anita, ten Bosch, Quirine A., L’Azou Jackson, Maïna, Bettis, Alison A., Bernuzzi, Mauro, Murphy, Georgina A. V., Tran, Quan M., Huber, John H., Siraj, Amir S., Bron, Gebbiena M., Elliott, Margaret, Hartlage, Carson S., Koh, Sojung, Strimbu, Kathyrn, Walters, Magdalene, Perkins, T. Alex, and Moore, Sean M.
- Subjects
viruses ,virus diseases - Abstract
Additional file 1: Table S1. Overview of data references. Table S2. Sizes of single reactive vaccination campaigns targeting the general population or healthcare workers (HCWs). SI Text. Sensitivity analysis and extended model limitations. Fig. S1. Spillover and reactive vaccination patterns for Lassa fever virus (LASV). Fig. S2. Spillover and reactive vaccination patterns for Middle Eastern respiratory virus (MERS-CoV). Fig. S3. Spillover and reactive vaccination patterns for Nipah virus (NiV). Fig. S4. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV). Fig. S5. Vaccine regimens required for Lassa fever virus (LASV). Fig. S6. Vaccine regimens required for Middle Eastern respiratory virus (MERS-CoV). Fig. S7. Vaccine regimens required for Nipah virus (NiV). Fig. S8. Vaccine regimens required for Rift Valley fever virus (RVFV). Fig. S9. Vaccine regimens required to vaccinate healthcare workers for Lassa fever virus (LASV). Fig. S10. Vaccine regimens required to vaccinate healthcare workers for Middle Eastern respiratory virus (MERS-CoV). Fig. S11. Vaccine regimens required to vaccinate healthcare workers for Nipah virus (NiV). Fig. S12. Vaccine regimens required to vaccinate veterinarians for Rift Valley fever virus (RVFV). Fig. S13. Vaccination impact sensitivity analysis for LASV. Fig. S14. Vaccination impact sensitivity analysis for NiV. Fig. S15. Vaccination impact sensitivity analysis for RVFV. Fig. S16. Number of cases under different R0 assumptions. Fig. S17. Number of vaccine regimens required under different R0 assumptions. Fig. S18. Number of vaccine regimens required for healthcare workers (HCWs) under different R0 assumptions. Fig. S19. Number of cases averted by vaccinating the general population under different R0 assumptions. Fig. S20. Fraction of cases averted by vaccinating the general population under different R0 assumptions. Fig. S21. Number of cases averted per vaccine regimen administered to the general population under different R0 assumptions. Fig. S22. Number of cases averted per vaccine regimen administered to healthcare workers (HCWs) under different R0 assumptions. Fig. S23. Spillover and reactive vaccination patterns for Lassa fever virus (LASV) within adm1 catchment areas. Fig. S24. Spillover and reactive vaccination patterns for Middle Eastern respiratory virus (MERS-CoV) within adm1 catchment areas. Fig. S25. Spillover and reactive vaccination patterns for Nipah virus (NiV) within adm1 catchment areas. Fig. S26. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV) within adm1 catchment areas. Fig. S27. Spillover and reactive vaccination patterns for Lassa fever virus (LASV) within adm1 hospital catchment areas. Fig. S28. Spillover and reactive vaccination patterns for Middle Eastern respiratory virus (MERS-CoV) within adm1 hospital catchment areas. Fig. S29. Spillover and reactive vaccination patterns for Nipah virus (NiV) within adm1 hospital catchment areas. Fig. S30. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV) within adm1 hospital catchment areas. Fig. S31. Geographic distribution of spillover cases and reactive vaccination campaigns for adm1 catchment areas. Fig. S32. Geographic distribution of spillover cases and reactive vaccination campaigns for adm1 hospital catchment areas. Fig. S33. Annual cases and reactive vaccination impacts for adm1 catchment areas. Fig. S34. Annual cases and reactive vaccination impacts for adm1 hospital-based catchment areas.
- Published
- 2022
- Full Text
- View/download PDF